Velcade Phase IV Trial Could Expand Label To First-Line Multiple Myeloma
A postmarketing trial assessing Velcade in previously untreated multiple myeloma patients could expand the label for the proteasome inhibitor to first-line use
You may also be interested in...
Approval of Millennium Pharmaceutical's Velcade (bortezomib) for second-line treatment of multiple myeloma will double the brand's current market opportunity, the company said
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011